http://www.theaustralian.com.au/business/opinion/nomad-building-u...

http://www.theaustralian.com.au/business/opinion/nomad-building-unilife-petsec-report-losses/story-e6frg9lo-1225912314108

Meanwhile, Unilife has pricked early investor optimism over commercialising its retractable syringe with a $29.7m loss ($14.5m when adjusted for non-cash items). A $9.7m shortfall ($5.7m adjusted) was incurred in the fourth quarter.

To be fair, Unilife, which is now domiciled in the US, is in the early stages of a supply deal with Sanofi-Aventis (the biggest purchaser of pre-filled syringes). So, full revenues are yet to flow and the timing depends on milestone payments. Still, investors knocked 5 per cent off the share price.